Trial Profile
A Two-centre, Randomised, Double-blind, Placebo-controlled, 2-period Cross-over Study to Evaluate the Effect of Treatment With Repeat Doses of Inhaled GSK256066 on the Allergen-induced Late Asthmatic Response in Subjects With Mild Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 256066 (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline Research & Development; GSK
- 26 May 2011 New trial record